Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AG-946 in anemia due to lower-risk myelodysplastic syndromes
2022-500609-42-00Phase 2Completed
- Sponsor
- Agios Pharmaceuticals
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 2, open-label trial of tebapivat in myelodysplastic syndrome (MDS) (2 arms), sponsored by Agios Pharmaceuticals. Primary endpoints: Hemoglobin response, Transfusion independence and 1 more. Started Feb 2023; status: completed.
02
Drugs
tebapivat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2022-500609-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500609-42-00.